Guardant Health will present 25 abstracts at ESMO 2026, highlighting new data on ctDNA liquid biopsy for cancer monitoring, including MRD surveillance and therapy resistance in lung, colorectal, and gastric cancers.New research examines how circulating tumor DNA testing could help detect cancer recurrence, track treatment response, and identify resistance across multiple cancer types.
The DNA-based test showed 96.8% specificity in cervical samples and could help physicians determine which patients need further testing for endometrial cancer.
The FDA has cleared Aptitude’s next-generation Metrix COVID Test, which the company says offers 3-fold higher sensitivity and 30% faster results compared to its EUA version.
Castle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.
As molecular diagnostics expand what laboratories can detect, laboratories are placing greater emphasis on matching the breadth of testing to the patient and how the results will be used.
General practitioner requests for AMH fertility tests rose more than 13-fold from 2011 to 2021, despite research showing these tests cannot predict natural conception, according to a Flinders University study of 1.4 million health records.
Werfen has launched a web-based platform designed to centralize autoimmune testing data, automate workflows, and integrate with laboratory information systems for high-volume clinical labs.
Labcorp and Thrive Global have launched the Thrive 5 Health Test, a direct-to-consumer panel combining five cardiometabolic biomarkers with behavioral guidance, now available through Labcorp OnDemand.
China’s NMPA has approved Quanterix and Innovita’s HD-X and SR-X immunoassay platforms and four blood-based neurology biomarker tests, expanding access to Alzheimer’s diagnostics in the Chinese clinical lab market.
Revvity has introduced the CE-IVDR-certified GSP T1D 3plex kit, a multiplex dried blood spot assay for early type 1 diabetes screening in children, designed to support population-level programs.
A Johns Hopkins study reports that adding three urine biomarkers to standard assessments raises the accuracy of predicting deceased donor kidney transplant success from 80% to 86%.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
Tampa General Hospital is the first in the Southeast to implement the MeMed BV host-response test in its emergency workflow, reporting a 33% reduction in cefepime use and 13% fewer hospitalizations, according to hospital-led research.